How Are AI Medical Tools Tested for Safety Before Release?

Formal Testing Applies to Tools Classified as Medical Devices

When an AI-based tool is intended for a specific medical use — such as assisting with a diagnostic task — and meets the criteria to be classified as a medical device, it generally undergoes a structured evaluation process before it can be marketed for that use. In the United States, this process typically involves the FDA, which reviews evidence submitted by the manufacturer demonstrating the tool’s safety and effectiveness for its specific, defined intended use. This evidence usually includes results from validation studies designed to assess how accurately or reliably the tool performs against an established reference standard for the task it’s meant to support.

An important element of rigorous validation is testing a tool on data that wasn’t used during its training, since evaluating a model only on data it already learned from can give a misleadingly optimistic picture of how well it will actually perform on new, unseen cases in real clinical use.

Regulatory Pathways Vary by Risk and Intended Use

Not every AI medical tool goes through an identical review process. Regulatory frameworks, including the FDA’s, generally apply different levels of scrutiny depending on factors like the potential risk associated with a tool’s intended use and how the tool is meant to function within clinical care — for instance, a tool intended to provide supplementary information to a clinician who retains full decision-making authority may be evaluated somewhat differently than a tool intended to play a more central role in a clinical decision. This risk-based approach to regulation is a common feature of medical device oversight more broadly, not something unique to AI.

Safety Monitoring Doesn’t Stop at Release

Pre-market testing and regulatory review, however thorough, cannot fully replicate every condition a tool might encounter once deployed across diverse real-world clinical settings, patient populations, and equipment. Because of this, post-market surveillance — ongoing monitoring of a tool’s real-world performance after release — is considered an important complement to initial testing. This can include mechanisms for manufacturers to report significant safety issues or malfunctions identified after deployment, allowing regulators and healthcare organizations to catch and address problems that weren’t apparent during pre-market testing, and in some cases leading to updated guidance, labeling changes, or further review of a tool already in use.

An Uneven Landscape Depending on Product Category

It’s worth noting that this level of formal safety testing and regulatory review applies specifically to tools that meet the criteria for medical device classification. Many consumer-facing AI health and wellness apps, which don’t make specific medical treatment claims, have historically faced a lighter regulatory pathway, meaning the rigor of safety testing can vary considerably across the broader landscape of AI health-related products.

Bottom Line

AI tools classified as medical devices are generally tested through validation studies demonstrating safety and effectiveness for their specific intended use, reviewed by regulators like the FDA, and subject to ongoing post-market monitoring after release — though this level of formal testing doesn’t apply uniformly across all AI health-related products, particularly general wellness apps without specific medical claims.

Go deeper

• How is safety testing for physical robots different from testing software only ai?
• Why Shouldn’t You Use AI as Your Only Source for Medical or Legal Advice?
• Can a robot trained in a simulation actually work reliably in the real world?